Skip to main content
Clinical Trials/DRKS00019842
DRKS00019842
Recruiting
未知

Prospective, randomized controlled, single center study evaluating additional respiration therapy with a PEP trainer to prevent pneumonia in patients with higher neutropenic risk under chemotherapeutic treatment of an acute myeloic leukemia - NeutroRespCare

Vivantes Klinikum Neukölln - Hämatologie, Onkologie und Palliativmedizin0 sites100 target enrollmentNovember 25, 2019

Overview

Phase
未知
Intervention
Not specified
Conditions
C92
Sponsor
Vivantes Klinikum Neukölln - Hämatologie, Onkologie und Palliativmedizin
Enrollment
100
Status
Recruiting
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
November 25, 2019
End Date
TBD
Last Updated
last year
Study Type
Interventional
Sex
All

Investigators

Sponsor
Vivantes Klinikum Neukölln - Hämatologie, Onkologie und Palliativmedizin

Eligibility Criteria

Inclusion Criteria

  • 1\. Patient with AML under first\-line high dose chemotherapy treated as in\-patient under curative intention (OR patients under high dose chemotherapy with consecutive autologous stem cell transplantation \- extended additional study population) .
  • 2\. Informed consent

Exclusion Criteria

  • 1\. Patient with diagnosed pulmonary infection at study start.
  • 2\. Patient with known primary immunodeficiency or uncontrolled HIV infection (Patients with known HIV infection but controlled disease, normal CD4 count and undetectable HIV virus load can participate).
  • 3\. Patients with COPD GOLD III or IV or severe bronchial asthma.
  • 4\. Patients with known infectious pulmonary disease.
  • 5\. Patient unwilling or able to perform physio\- and respiration therapy

Outcomes

Primary Outcomes

Not specified

Similar Trials